| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Porgaviximab/Larcaviximab/Cosfroviximab | c2G4-N; c4G7; c13C6 | Phase 3 Clinical | Mapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology Laboratory | Hemorrhagic Fever, Ebola | Details |
| MIL-77 | MIL-77 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical Sciences | Hemorrhagic Fever, Ebola | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ansuvimab | VRC-EBOMAB092-00-AB; MAb114; MAb-114 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad | Ebanga | United States | Hemorrhagic Fever, Ebola | Ridgeback Biotherapeutics Lp | 2020-12-21 | Hemorrhagic Fever, Ebola | Details |
| Atoltivimab/Maftivimab/Odesivimab | REGN3470-3471-3479; REGN-EB3 | Approved | Inmazeb | United States | Hemorrhagic Fever, Ebola | Regeneron Pharmaceuticals Inc | 2020-10-14 | Hemorrhagic Fever, Ebola | Details |

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호



